Format

Send to

Choose Destination
Front Immunol. 2019 Jul 19;10:1719. doi: 10.3389/fimmu.2019.01719. eCollection 2019.

T Cell Dysfunction in Cancer Immunity and Immunotherapy.

Author information

1
Department of General Surgery, Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
2
Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
3
Department of Rehabilitation, Huai'an Second People's Hospital, and the Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
4
Reproductive Medicine Center, Renmin Hospital of Wuhan University, Wuhan, China.

Abstract

In cancer, T cells become dysfunctional owing to persistent antigen exposure. Dysfunctional T cells are characterized by reduced proliferative capacity, decreased effector function, and overexpression of multiple inhibitory receptors. Due to the presence of various inhibitory signals in the complex tumor microenvironment, tumor-specific T cells have distinct dysfunction states. Therapeutic reactivation of tumor-specific T cells has yielded good results in cancer patients. Here, we review the hallmarks of T cell dysfunction in cancer. Also, we discuss the relationship between T cell dysfunction and cancer immunotherapy.

KEYWORDS:

T cell dysfunction; cancer; immunity; immunotherapy; tumor microenvironment

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center